THERAVANCE BIOPHARMA INC (TBPH)
KYG8807B1068 - Common Stock
We assign a fundamental rating of 4 out of 10 to TBPH. TBPH was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TBPH as it has an excellent financial health rating, but there are worries on the profitability. TBPH is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TBPH had negative earnings in the past year.
TBPH had a negative operating cash flow in the past year.
TBPH had negative earnings in 4 of the past 5 years.
TBPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TBPH's Return On Assets of -14.45% is fine compared to the rest of the industry. TBPH outperforms 68.72% of its industry peers.
With a decent Return On Equity value of -25.92%, TBPH is doing good in the industry, outperforming 71.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.45% | ||
| ROE | -25.92% | ||
| ROIC | N/A |
ROA(3y)25.31%
ROA(5y)-8.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TBPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBPH has been reduced compared to 1 year ago.
Compared to 5 years ago, TBPH has less shares outstanding
There is no outstanding debt for TBPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TBPH has an Altman-Z score of -1.66. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
TBPH has a Altman-Z score (-1.66) which is in line with its industry peers.
There is no outstanding debt for TBPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.66 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
TBPH has a Current Ratio of 5.39. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH's Current ratio of 5.39 is fine compared to the rest of the industry. TBPH outperforms 70.26% of its industry peers.
TBPH has a Quick Ratio of 5.39. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH has a Quick ratio of 5.39. This is in the better half of the industry: TBPH outperforms 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.39 | ||
| Quick Ratio | 5.39 |
3. Growth
3.1 Past
The earnings per share for TBPH have decreased strongly by -44.78% in the last year.
Looking at the last year, TBPH shows a quite strong growth in Revenue. The Revenue has grown by 11.61% in the last year.
TBPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.01% yearly.
EPS 1Y (TTM)-44.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.33%
Revenue 1Y (TTM)11.61%
Revenue growth 3Y-7.22%
Revenue growth 5Y-1.01%
Revenue growth Q2Q20.31%
3.2 Future
Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 37.55% on average per year.
Based on estimates for the next years, TBPH will show a very strong growth in Revenue. The Revenue will grow by 28.18% on average per year.
EPS Next Y32.21%
EPS Next 2Y28.77%
EPS Next 3Y49.41%
EPS Next 5Y37.55%
Revenue Next Year29.17%
Revenue Next 2Y22.52%
Revenue Next 3Y28.96%
Revenue Next 5Y28.18%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TBPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TBPH's earnings are expected to grow with 49.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y49.41%
5. Dividend
5.1 Amount
No dividends for TBPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
THERAVANCE BIOPHARMA INC
NASDAQ:TBPH (5/9/2024, 2:55:03 PM)
9.47
-0.02 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap459.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.45% | ||
| ROE | -25.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.39 | ||
| Quick Ratio | 5.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-44.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.61%
Revenue growth 3Y-7.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y